We are live on ! Find out more
CODX

Co-Diagnostics

88 hedge funds and large institutions have $61M invested in Co-Diagnostics in 2021 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 19 increasing their positions, 32 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.21% less ownership

Funds ownership: 1.05%0.84% (-0.21%)

7% less funds holding

Funds holding: 9588 (-7)

24% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 29

29% less capital invested

Capital invested by funds: $85.7M → $61M (-$24.7M)

41% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 32

48% less call options, than puts

Call options by funds: $4.14M | Put options by funds: $7.96M

Holders
88
Holders Change
-7
Holders Change %
-7.37%
% of All Funds
1.53%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
22
Increased
19
Reduced
32
Closed
29
Calls
$4.14M
Puts
$7.96M
Net Calls
-$3.82M
Net Calls Change
-$845K

CODX Hedge Fund Activity: Q2 2021 in Review

88 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q2 2021, worth a combined $61M — down 29% from $85.7M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of CODX and 22 opened new positions — a net loss of 7 holders — while 32 trimmed existing stakes and 19 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $3.83M. The largest seller was BlackRock, cutting an estimated $12.3M.

  • 88 institutional investors held Co-Diagnostics (CODX) as of Q2 2021, down from 95 in Q1 2021.
  • Funds reported $61M of Co-Diagnostics stock for Q2 2021, down 29% quarter-over-quarter.
  • 22 funds opened new Co-Diagnostics positions in Q2 2021 and 29 closed out, a net change of -7 holders.
  • The largest Co-Diagnostics buyer in Q2 2021 was Millennium Management, an estimated $3.83M added.
  • The largest Co-Diagnostics seller in Q2 2021 was BlackRock, an estimated $12.3M sold.

Based on aggregated 13F filings for Q2 2021.